News: Lupin Ltd (LUPN.NS)
26 Dec 2014
Fri, Dec 12 2014
* Regulator says continues work on expanding price control list (Adds comment from Lupin)
MUMBAI, Oct 28 - Indian generic drugmaker Lupin Ltd reported a 54 percent jump in second-quarter profit beating analysts estimates, helped by robust sales in its domestic business and the United States, its largest market.
FRANKFURT - German drugmaker Merck KGaA said it struck a deal with Lupin Limited to market some of the Indian drugmaker's cardiovascular and diabetes treatments in emerging markets.
FRANKFURT, Sept 16 - German drugmaker Merck KGaA said it struck a deal with Lupin Limited to market some of the Indian drugmaker's cardiovascular and diabetes treatments in emerging markets.
(Corrects to say Salix will get upfront payment from Lupin in second paragraph)
Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)
* Q1 net profit up 56 pct at 6.25 bln rupees, beats estimates
MUMBAI, July 30 - Lupin Ltd, India's fourth-largest drugmaker by sales, reported a higher-than-expected profit in the first quarter, helped mainly by higher sales in the United States and India, and lower expenses.
LONDON/MUMBAI - Indian generics firm Lupin , some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline (GSK) , five sources familiar with the matter said.